About Cybin Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. About Stifel Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC and Century Securities Associates, Inc. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and m
Cybin Inc Shares Commence Trading on the OTCQB Venture Market on March 8, 2021
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Cybin Inc Announces Uplisting to OTCQB Venture Market
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Cybin Inc. Releases Financial Highlights and Provides Business Update
Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline Partnership with Kernel provides access to neuroimaging … Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline Partnership with Kernel provides access to neuroimaging technology, enabling the potential quantification of psychedelic therapeutics –
Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics psychiatry s brave new world. The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by leading pharmaceutical companies. A report from Data Bridge Market Research reported that the global psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market g